Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Treasury Shares: 2022-2025

Historic Treasury Shares for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $2.8 million.

  • Day One Biopharmaceuticals' Treasury Shares rose 46.17% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 46.17%. This contributed to the annual value of $1.8 million for FY2024, which is 86.89% up from last year.
  • Day One Biopharmaceuticals' Treasury Shares amounted to $2.8 million in Q3 2025, which was down 6.89% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Treasury Shares ranged from a high of $3.0 million in Q2 2025 and a low of $392,757 during Q1 2022.
  • Over the past 3 years, Day One Biopharmaceuticals' median Treasury Shares value was $1.9 million (recorded in 2024), while the average stood at $1.8 million.
  • Data for Day One Biopharmaceuticals' Treasury Shares shows a peak YoY surged of 144.63% (in 2024) over the last 5 years.
  • Over the past 4 years, Day One Biopharmaceuticals' Treasury Shares (Quarterly) stood at $485,351 in 2022, then surged by 95.60% to $949,370 in 2023, then surged by 86.89% to $1.8 million in 2024, then surged by 46.17% to $2.8 million in 2025.
  • Its Treasury Shares was $2.8 million in Q3 2025, compared to $3.0 million in Q2 2025 and $2.9 million in Q1 2025.